U.S. and North Macedonia agree on new trade framework to promote reciprocal, fair, and balanced economic relations • Establishes principles for trade negotiations and dispute resolution • Aims to enhance market access and reduce trade barriers • Sets timeline for implementation and review processes • Focuses on strengthening economic partnership and cooperation www.whitehouse.gov/bri... #WhiteHouse #BriefingsStatements

President Trump highlights renewed focus on clean coal industry during recent remarks * Emphasizes technological advancements in coal cleaning * Promises support for coal industry jobs and infrastructure * Calls for policies balancing energy needs and environmental concerns * Reaffirms commitment to "beautiful, clean coal" as a national resource www.whitehouse.gov/art... #WhiteHouse #Articles

President Lincoln's birthday observed on February 12, 2026, with official commemorations and educational events nationwide. * Presidential proclamation issued recognizing Lincoln's legacy * Schools and institutions hold special programs * Focus on civil rights and national unity themes * Commemorations include wreath-laying ceremonies * Reflects ongoing emphasis on Lincoln's historical significance www.whitehouse.gov/bri... #WhiteHouse #BriefingsStatements

First Lady facilitates reunification of Russian and Ukrainian children * Coordinates with international agencies for child repatriation * Focuses on humanitarian and diplomatic efforts * Emphasizes importance of family reunification in conflict zones * Details ongoing cooperation with Russian and Ukrainian authorities * Aims to expedite process amid ongoing tensions www.whitehouse.gov/bri... #WhiteHouse #BriefingsStatements

Republic Services (RSG) appoints Ian Craig to board, expanding to 13 members, effective February 10, 2026 - Craig, CEO of Coca-Cola FEMSA, brings expertise in sustainability and digital transformation - He will serve on Audit and Sustainability committees with prorated RSU and cash compensation - Quarterly dividend declared at $0.625 per share, payable April 15, 2026 #Form8K #BoardUpdate #InvestorUpdate Full summary: www.perivis.com/note/a... $RSG.US

Roku (ROKU) reports $4.737B revenue in 2025 with $80.5M net income, marking a profitable turnaround and record free cash flow of $483.6M - Platform revenue grew 18% to $4.145B, driving adjusted EBITDA up 119% to $481.5M - Q4 operating income turned positive at $66M versus a $39.1M loss a year ago - Repurchased $150M in shares under a $400M buyback program during 2025 #Form8K #EarningsUpdate #InvestorUpdate Full summary: www.perivis.com/note/8... $ROKU.US

CRISPR Therapeutics (CRSP) reports $54M Q4 revenue from CASGEVY with 64 patients treated in 2025 and plans pediatric regulatory submissions in H1 2026 - CASGEVY approved in US, EU, UK, Canada, and Middle East; 90% of eligible US patients have reimbursed access - 147 patients initiated treatment process in 2025, nearly triple 2024 levels - In vivo liver editing and siRNA programs advancing with multiple clinical trials planned for 2026 - Pediatric data recognized at ASH and FDA granted National Priority Voucher for review #Form8K #EarningsUpdate #InvestorUpdate Full summary: www.perivis.com/note/0... $CRSP.US

Thermo Fisher Scientific (TMO) raises $4.8B in senior notes to fund Clario Holdings acquisition and corporate needs - Issued four tranches with maturities from 2031 to 2046, fixed rates between 4.215% and 5.546% - Net proceeds of approximately $3.76B after underwriting fees - Notes include par call redemption features and change-of-control repurchase rights - Offering led by Deutsche Bank, RBC, SMBC Nikko, and Wells Fargo #Form8K #Financing #StrategicDeal Full summary: www.perivis.com/note/c... $TMO.US

Equinix (EQIX) launches new Executive Severance Plan standardizing benefits for senior executives and updates CEO severance agreement effective February 6, 2026. - Plan covers all executive officers except CEO, replacing prior severance arrangements with uniform benefits. - Provides 12 months’ salary plus target bonus and continued equity vesting for terminations without cause. - Enhanced change-in-control benefits include 2x severance and accelerated equity vesting. - CEO’s amended agreement removes term limit and adds 12 months’ equity vesting and outplacement services. #Form8K #ExecutiveComp #CorporateUpdate Full summary: www.perivis.com/note/7... $EQIX.US

10x Genomics (TXG) reports Q4 2025 revenue of $166M, up 1%, with full-year core revenue down 2% excluding $44.1M patent settlement - Gross margin improved to 68% in Q4 2025; operating expenses fell 18% year-over-year - Cash and equivalents rose $130M to $523.4M, strengthening liquidity - New AI-driven cancer and autoimmune research partnerships launched with leading institutes #Form8K #EarningsUpdate #StrategicDeal Full summary: www.perivis.com/note/a... $TXG.US

Pacific Biosciences (PACB) reports Q4 2025 revenue of $44.6M, up 14% YoY, with Vega system placements surging to 42 units in the quarter - Full year 2025 revenue rose 4% to $160M, driven by 17% growth in consumables to $82M - GAAP gross margin improved to 40% in Q4 from 31% a year ago, while GAAP net loss was $40.4M - Cash and investments declined to $279.5M from $389.9M at year-end 2024 #Form8K #EarningsUpdate #InvestorUpdate Full summary: www.perivis.com/note/0... $PACB.US

Federal Reserve approves Honduras-based credit union’s Miami office • Application by Cooperativa de Ahorro y Credito Elga, Ltda. approved • First U.S. presence for the institution, based in Tegucigalpa • Establishes a representative office in Miami, Florida • Signifies expansion of international banking applications • No immediate policy or rate implications Original Press Release: www.federalreserve.gov... #FederalReserve #OrdersOnBankingApplications

Former Regions Bank employee barred for misappropriating customer funds • Consent prohibition order issued against Nicole M. Ramsey • Alleged misappropriation of customer funds at Birmingham branch • Enforcement action signals increased scrutiny on bank compliance • No monetary penalties announced; focus on misconduct prevention Original Press Release: www.federalreserve.gov... #FederalReserve #EnforcementActions

Bulgaria joins the euro area amid smooth cash changeover and rising influence in ECB policymaking • Euro cash transition completed with 70% circulation by Jan 2026 • Bulgaria gains seat at ECB policy table, active in Eurosystem committees • Emphasizes scale benefits: financial integration, resilience, infrastructure innovation • Highlights need for domestic reforms: governance, public investment, fiscal sustainability • Growth expected to outpace euro area, with risks of overshoot; macroprudential measures in place Original Press Release: www.ecb.europa.eu//pre... #ECB #EuropeanCentralBank

FDA removes boxed warnings on 6 menopausal hormone therapies to improve risk clarity and support informed women’s choices. • Warnings on cardiovascular, breast cancer, and dementia risks eliminated after review • Includes systemic, topical, estrogen, progestogen, and combination therapies • Initiated in Nov 2025, with 29 companies submitting label updates • Aims to enhance accurate risk-benefit understanding for women and clinicians • Supports informed decision-making for menopause symptom management Original Press Release: www.fda.gov/news-event... #FDA #USFDA

FDA sets new acceptable intake limits for nitrosamine impurities in drugs, updates implementation timelines, and enhances testing guidance. • AI limits based on carcinogenic potency categorization and compound-specific data • Interim limits for certain nitrosamines, with phased implementation through 2026 • New analytical and safety testing methods recommended for confirmatory detection • Updated timelines for risk assessment, testing, and submission of mitigation strategies • Focus on controlling NDSRIs in drug manufacturing to mitigate carcinogenic risks Original Press Release: www.fda.gov/regulatory... #FDA #USFDA

FDA clarifies expanded access pathways for investigational drugs amid new statutory requirements • Webinar on regulatory framework, submission process, and reporting for expanded access programs • Covers three categories: individual patient, intermediate-size, treatment INDs • Focus on compliance, resource tools, and recent legislative updates (21st Century Cures Act, FDARA) • Targeted at sponsors, clinicians, IRBs, patient advocates, and regulators • CE credits available for industry and healthcare professionals Original Press Release: www.fda.gov/drugs/news... #FDA #USFDA

Allergy alert: Undeclared milk and soy in Junebar snack bars prompts recall • Affected products: Chocolate Cherry, Peanut Butter Chocolate Chip Junebars, batch L1300/L1301 • Distributed in NY, January 2026, via retailers and website orders • Cause: Sourcing oversight led to inclusion of milk/soy-containing chocolate chips • Risk: Severe allergic reactions in sensitive individuals • Consumer action: Return for full refund, contact 315-226-3339 or contact@junebars.com Original Press Release: www.fda.gov/safety/rec... #FDA #USFDA

Recall of Wellsley Farms Atlantic Salmon at BJ’s due to Listeria risk • Lot 3896, sold Jan 31–Feb 7, 2026, in multiple states • Potential contamination with Listeria monocytogenes identified by FDA sampling • No illnesses reported; risk for pregnant women includes miscarriage, stillbirth • Product in 2-lb bags, UPC 888670025963, lot number on reverse • Company investigating contamination source, taking corrective steps • Consumers advised to contact 1-888-628-0730 for refunds and disposal guidance Original Press Release: www.fda.gov/safety/rec... #FDA #USFDA

FDA removes boxed warnings on 6 menopausal hormone therapies to improve risk clarity and support informed women’s choices. • Warnings on cardiovascular, breast cancer, and dementia risks eliminated after review • Includes systemic, topical, estrogen, progestogen, and combination therapies • Initiated in Nov 2025, with 29 companies submitting label updates • Aims to enhance accurate risk-benefit understanding for women with menopause symptoms • Supports informed decision-making amid low current HRT utilization Original Press Release: www.fda.gov/news-event... #FDA #USFDA

FDA collaborates with public-private consortia to bridge science gaps in drug development, advancing regulatory tools and innovation. - Engages with multiple stakeholders including academia, industry, and government - Facilitates development of biomarkers, imaging, genetic tests, and digital tools - Uses formal processes for staff participation via MAPP 4100.2 - Active in initiatives like AMP, BioCelerate, and the Critical Path Consortium - Focuses on accelerating medicines and improving regulatory science Original Press Release: www.fda.gov/drugs/scie... #FDA #USFDA

FDA completes key PDUFA VI deliverables on drug safety, data standards, and stakeholder engagement; highlights progress in regulatory modernization. • Sentinel system assessment published 9/30/2022 • Multiple public meetings on electronic data standards (2018-2022) • Final guidance on adaptive trial designs issued 11/29/2019 • Independent reviews on combination products and safety signals (2020-2023) • Patient-focused guidance and workshops advancing clinical trial methods • Updates on staffing, financial plans, and electronic submission metrics Original Press Release: www.fda.gov/industry/p... #FDA #USFDA

Menopausal hormone therapies update with new prescribing info for Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva • Updated labels include safety and efficacy data • Prometrium (progestogen), Divigel, Cenestin, Enjuvia (estrogens) • Estring (vaginal estrogen), Bijuva (estrogen + progestogen) • Affects prescribing practices and patient management Original Press Release: www.fda.gov/drugs/drug... #FDA #USFDA

FDA proposes removing cardiovascular, breast cancer, and probable dementia risks from menopausal hormone therapy Boxed Warnings to clarify benefit/risk profile. • Removes language on cardiovascular, breast cancer, probable dementia risks from Boxed Warning • Retains endometrial cancer warning for systemic estrogen-alone products • Adds guidance on initiating therapy for women under 60 or within 10 years of menopause • Incorporates WHI data for women aged 50-59 in labeling • Condenses safety info for local vaginal estrogen products • Updates prescribing info across all MHT formulations Original Press Release: www.fda.gov/drugs/drug... #FDA #USFDA

FDA approves first portable device delivering electrical fields for pancreatic cancer treatment - Optune Pax by Novocure uses tumor treating fields to disrupt cancer cell division - Approved via premarket approval pathway after clinical trial showing ~2-month survival benefit - Device worn with adhesive patches, enabling continuous, at-home therapy - Breakthrough Device designation granted in Dec 2024 to expedite access - Addresses urgent need amid 67,440 new diagnoses in 2025 Original Press Release: www.fda.gov/news-event... #FDA #USFDA

FDA enhances oversight of prescription stimulants amid rising use and overdose risks • Doubling of prescriptions from 2011-2022, especially in adults • New label updates and safety warnings for stimulant medications • Funding research on stimulant use disorder treatments and adult ADHD management • Initiatives to promote safe prescribing, disposal, and online purchasing controls • Efforts to develop FDA-approved pharmacotherapies for stimulant use disorder Original Press Release: www.fda.gov/drugs/info... #FDA #USFDA

FDA finalizes guidance on antimicrobial use in food animals amid declining sales and increased surveillance efforts * Updates include defining durations of use for antibiotics in food animals. * 2.8 million resistant infections annually in US, over 35,000 deaths. * New antimicrobial susceptibility testing devices approved, including rapid diagnostics. * 2023 antimicrobial sales in food animals down 2% from 2022, 37% since 2015 peak. * Public comment period open for NARMS strategic plan through March 2025. * Ongoing collaborations with CDC, USDA, and international partners to combat AMR. Original Press Release: www.fda.gov/emergency-... #FDA #USFDA

FDA extends EUAs for COVID-19 treatments including Pemgarda, Gohibic, Kineret, Lagevrio, Paxlovid, and Olumiant amid PHE expiration; existing authorizations remain in effect. • Pemgarda EUA reissued with amendments through September 2025 • Gohibic authorized for hospitalized adults within 48 hours of ventilation • Kineret approved for at-risk adults with COVID-19 pneumonia • Lagevrio authorized for high-risk adults with mild-to-moderate COVID-19 • Paxlovid treatment expanded to pediatric patients, now also approved for adults • Olumiant authorized for pediatric COVID-19 in severe cases • PHE ending on May 11, 2023, but EUAs continue if criteria met Original Press Release: www.fda.gov/drugs/emer... #FDA #USFDA

Government of India Securities Conversion/Switch Operation Conversion/Switch of Government of India Dated Securities – February 12, 2026: The Government of India conducted conversion/switch operations with the Reserve Bank on February 12, 2026, involving buyback of securities maturing in FY 2026-27 and issuance of new securities based on FBIL prices. These operations aim to smoothen the government's liability profile and support market development. Original Press Release: www.rbi.org.in/scripts... #RBI #CentralBank #India

Seagate Technology Holdings (STX) announces $600M private exchange offer of 3.50% Senior Notes due 2028 for cash and new shares, closing around Feb 17, 2026 - Exchange involves $599.2M cash plus newly issued ordinary shares determined by Feb 12, 2026 market prices - Transaction reduces outstanding debt by $600M and increases share count via private placement - Targeted to select noteholders, exempt from Securities Act registration, signed off by CFO Gianluca Romano #Form8K #Debt #EquityIssuance Full summary: www.perivis.com/note/6... $STX.US